MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/22/2016 00:49 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 16.64% ($0.11) From $0.685 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [09/22/2016 00:49 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 10.80% ($0.07) From $0.685 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [09/22/2016 00:49 PDT] MNKD Are Seasonally Ripe To Go Down In the Next Five Weeks
• [08/25/2016 04:31 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 19.89% ($0.17) From $0.870 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/25/2016 04:31 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 13.79% ($0.12) From $0.870 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/25/2016 04:31 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 9.08% ($0.08) From $0.870 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/25/2016 04:31 PDT] MNKD Expected to Trade Down After Bearish Patterns Develop
• [08/24/2016 00:53 PDT] MNKD Are Seasonally Ripe To Go Up In the Next Five Weeks